Welcome, Guest
Username: Password: Remember me

TOPIC: IG..(MC $75 M) 3x Product launched,,2 or 3 FDA approvals imminent // 11x awaiting FDA approval

IG..(MC $75 M) 3x Product launched,,2 or 3 FDA approvals imminent // 11x awaiting FDA approval 5 years 11 months ago #3756


A REAL Undiscovered Stock with Huge Upside Potential !! GLTA


They have 11 Products awaiting FDA approval , 3 Products already launched in USA and another Product will enter the Market in this Q . 3 more ANDA filings coming before Year End oh and they will reach Profitability in this year .


Ticker ( NYSE: IG )

Market Cap : $75 M
Cash : $2.3 M
Price : $1.70

Shares Out : 43 M .....(31 Million Shares held by Big Investors)
Float : 11 M

Summary :

1) Laughable Market Cap of $75 M
2) Cash for 12 Months ....... Profitability before Year End
3) 3x Products launched in USA since December 2012
4) Fourth Product will enter the Market in this Quarter
5) 11x Products under review by FDA many of these will get FDA approval within 12 Months
6) Another 3x ANDA filings coming before year end
7) 72% of all Shares Outstanding held by Insiders & Institutions and still buying more
8) Small Float of only ~11 Million Shares

I think targets of $8-12 within 1-2 years is more realistic than Roth Capitals $3.50 .


Massive buying by Institutions
http://data.cnbc.com/quotes/IG/tab/8



and buying by Management
http://www.secform4.com/insider-trading/352998.htm


From latest Q-Results :

IGI’s President and Chief Executive Officer, Jason Grenfell-Gardner, stated, “I am extremely pleased with the progress we have made to obtain IGI’s current market position in our first three IGI labeled topical pharmaceutical products. We are ready to launch our fourth product, econazole nitrate cream 1%, which we acquired earlier this year, during the third quarter of 2013 pending final FDA approval of our site transfer. We have expanded our IGI label customer base for our existing product lines, and we continue to explore opportunities to potentially expand our product portfolio. Our formulation and manufacturing contract services revenue continued to grow, and has increased 10% over 2012 year to date.” Mr. Grenfell-Gardner continued, “Our research and development team has filed three ANDAs in 2013, one in January, one in April, and one in July, which brings our total filings pending with the US FDA to 11. Our team is committed to our plan to file at least six ANDAs in 2013. We remain on track for our target to at least double our 2012 total revenue and achieve profitability in 2013


Roth starts IGI Labs at buy
August 7, 2013

Roth Capital Partners has initiated coverage of IGI Laboratories (NYSE MKT:IG) with a “buy” rating and 12-month price target of $3.50, saying the impetus for the rating is “expectations for the company’s internal proprietary generic pipeline to come to fruition and drive sustainable earnings profitability.”

Analyst Scott Henry writes that IGI Labs has 11 ANDAs at the FDA, and “we expect approvals starting in late 2013/early 2014. We view this pipeline as the engine for sustainable profitability in 2014-plus.”

In addition, he said IGI is currently launching two new products – Synalar and econazole nitrate – that could have combined annual peak revenue potential approaching $10-million. These compounds could take the company to earnings breakeven, he added.

“We believe that topicals are among the most attractive segments for an emerging generics company, with higher barriers to entry and better pricing,” he said. “We believe that this further makes IGI Labs a target for industry consolidation.”
The administrator has disabled public write access.